BSE filing, NSE: ZYDUSLIFE. Summary written from the filing by ALFA Finder's alert engine.
Zydus Lifesciences Ltd: key numbers
- Share price
- ₹1,175.50
- Market cap
- ₹1,18,283 Cr
- Revenue (annual)
- ₹27,148 Cr
- Net profit (annual)
- ₹5,040 Cr
- P/E (TTM)
- 26.2×Sector 46.1×
- Promoter holding
- 75.01%+0.00% QoQ
- FII holding
- 7.05%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zydus Lifesciences Ltd
All →Zydus Lifesciences Partnership
Zydus Lifesciences' division Zylidac Bio partnered with Prolific Machines to scale their next-generation biologics manufacturing platform for GMP production.
Zydus Lifesciences Regulatory Approval
Zydus Lifesciences received USFDA approval for its Estradiol-Levonorgestrel Transdermal System ANDA, designated as a CGT. The product is eligible for 180-day exclusivity upon first commercial marketing.
Zydus Lifesciences Board Meeting Date
Zydus Lifesciences intimated a board meeting on 4 Nov 2026 to approve unaudited Q1/H1 FY27 results. Trading window remains closed until 6 Nov 2026.
Zydus Lifesciences Capacity Expansion: ₹190 Cr Investment
Zydus' JV with Sunshine Healthcare signed a BOI agreement to establish a pharma plant in Sri Lanka. Investment exceeds USD 20 million (~₹190 Cr), targeting 2028.
- Value
- ₹190.0 Cr
Zydus Lifesciences Business Update
Zydus Lifesciences presented post-hoc analysis from its EPICS-III clinical trial for Saroglitazar at ACG 2026. The drug remains under regulatory review for PBC treatment.
Zydus Lifesciences Other Announcement
Zydus Lifesciences Limited submitted the quarterly certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming share dematerialization compliance for the quarter ended September 30, 2026.
Other other announcement announcements
All →Avantel Other Announcement
Avantel dispatched Reg 36(1)(b) letters to shareholders without registered emails, providing a web link to the Postal Ballot notice. The letter facilitates email registration for remote e-voting.
Infosys Other Announcement
Infosys designated person sold 4,000 ADRs on NYSE for ₹0.47 Crore. Post-sale holding reduced from 8,586 to 4,586 units.
- Value
- ₹0.47 Cr
Net Avenue Technologies Other Announcement
Net Avenue Technologies informed NSE that the Reg 27 corporate governance report is not applicable as its securities are listed on the SME platform. No business or financial event is disclosed.
Vishvprabha Ventures Other Announcement
Vishvprabha Ventures has filed its quarterly shareholding pattern for the period ended 30 September 2026. Promoter holding is 61.31%, with public shareholding of 38.69%.
Lexora Global Other Announcement
Lexora Global Ltd informed BSE of its updated company website address. The change from www.lexoragloble.com to www.lexoraglobal.in is purely administrative.
Refractory Shapes Other Announcement
Refractory Shapes Ltd filed its Integrated Governance filing for the quarter and half year ended 30 Sep 2026. It claims exemption from the Corporate Governance Report and reported zero investor grievances.